Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 7/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | STS | P08842 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19995685 | 0.89 | KDM1A (0.54) | SYKMEN1KMT2AGPR119P2RX7 | |
| SCHEMBL25231274 | 0.87 | SYK (0.47) | SYKMEN1KMT2AGPR119P2RX7 | |
| SCHEMBL19448421 | 0.83 | ITGB3 (0.43) | SYKMEN1KMT2AGPR119P2RX7 | |
| SCHEMBL20913878 | 0.83 | ITGB3 (0.43) | SYKMEN1KMT2AGPR119P2RX7 | |
| SCHEMBL22233159 | 0.83 | SYK (0.46) | SYKMEN1KMT2AGPR119P2RX7 | |
| SCHEMBL3273006 | 0.83 | KDM1A (0.52) | SYKMEN1KMT2ASMN1; SMN2HTT | |
| SCHEMBL31310115 | 0.82 | MEN1 (0.44) | SYKMEN1KMT2AGPR119P2RX7 | |
| SCHEMBL30690286 | 0.81 | MEN1 (0.46) | SYKMEN1KMT2AGPR119P2RX7 | |
| SCHEMBL19995751 | 0.81 | MEN1 (0.49) | SYKMEN1KMT2AGPR119P2RX7 | |
| SCHEMBL6636967 | 0.81 | MEN1 (0.49) | SYKMEN1KMT2AGPR119P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113950477-B | Granulin precursor modulators and methods of use thereof | 阿库达医疗公司 | 2024-07-05 | — | — | CN | disclosed |
| US-20220251084-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | JANSSEN PHARMACEUTICA NV (BE) | 2022-08-11 | — | — | US | disclosed |
| EP-3983401-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | Arkuda Therapeutics (US) | 2022-04-20 | — | — | EP | disclosed |
| CN-113950477-A | Modulators of progranulin and methods of use thereof | 阿库达医疗公司 | 2022-01-18 | — | — | CN | disclosed |
| WO-2020252222-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS (US) | 2020-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220251084-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | GRN, PRNP, PSEN2 | SYK 4883/4885MEN1 1138/4885KMT2A 4519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.